ABSTRACT
Cytolytic T lymphocytes (CTLs) have been shown to mediate tum or rejection in several animal models. In humans, tum or immunologists are working under the assumption that T lymphocytes might be able to eradicate cancer cells as effectively as they do with virus-infected cells. An exciting challenge is to identify on cancer cells, specific antigens targeted by CTLs, and then to manipulate these antigens so that they become capable of initiating or amplifying a patients native immune response, which would otherwise be insufficient.
